سعر رويانوكسيكام 8 مجم 2024

Lornoxicam 8 mg film-coated tablets (20 per pack) from Medizen Pharmaceutical Industries, an oxicam NSAID for pain and inflammation.

• Short-term relief of acute mild to moderate pain.Population: AdultsHealth Products Regulatory Authority (HPRA), Ireland
• Symptomatic relief of pain and inflammation in osteoarthritis.Population: AdultsHealth Products Regulatory Authority (HPRA), Ireland
• Symptomatic relief of pain and inflammation in rheumatoid arthritis.Population: AdultsHealth Products Regulatory Authority (HPRA), Ireland

• About 20% of patients have adverse reactions; most frequent are nausea, dyspepsia, indigestion, abdominal pain, vomiting and diarrhoea (generally <10%). Oedema, hypertension and cardiac failure reported with NSAIDs.International label, same formulation · Health Products Regulatory Authority (HPRA), Ireland

• Hypersensitivity to lornoxicam or excipients, or (asthma, rhinitis, angioedema, urticaria) to other NSAIDs including aspirin.International label, same formulation · Health Products Regulatory Authority (HPRA), Ireland
• Thrombocytopenia; gastrointestinal, cerebrovascular or other bleeding disorders; history of NSAID-related GI bleeding/perforation; active or recurrent peptic ulcer/haemorrhage.International label, same formulation · Health Products Regulatory Authority (HPRA), Ireland
• Severe heart failure, severe hepatic impairment, severe renal impairment (serum creatinine >700 micromol/L), third trimester of pregnancy.International label, same formulation · Health Products Regulatory Authority (HPRA), Ireland

• Use only after careful risk-benefit assessment in mild-moderate renal impairment, coagulation disorders, hepatic impairment, elderly, history of GI disease, hypertension and/or heart failure; NSAIDs may slightly increase arterial thrombotic risk.International label, same formulation · Health Products Regulatory Authority (HPRA), Ireland
• GI bleeding, ulceration or perforation, sometimes fatal, can occur, particularly in the elderly; monitor renal function in at-risk patients.International label, same formulation · Health Products Regulatory Authority (HPRA), Ireland

• No adequate human data; prostaglandin synthesis inhibitors may adversely affect pregnancy and embryo-fetal development (miscarriage, cardiac malformation).International label, same formulation · Health Products Regulatory Authority (HPRA), Ireland
• No human data; excreted in rat milk in relatively high concentrations; should not be used in breastfeeding women.International label, same formulation · Health Products Regulatory Authority (HPRA), Ireland

• Lornoxicam: Inhibits COX-1 and COX-2, reducing prostaglandin synthesis.